Scientific Advisory Board
Dr. Furman is a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology at the Weill Medical College and the New York Presbyterian Hospital.
He is the director of CLL Center and the Waldenstrom’s Macroglobulinemia program. Dr. Furman is an internationally well-recognized expert in CLL and has led many clinical trials in B cell leukemias and lymphomas. The most recent CLL trials include Ibrutinib sponsored by Pharmacyclics and CAL-101 phase III trials sponsored by Gilead. He will design and conduct the clinical trials for Rel inhibitors in CLL, as well as advising ImmuneTarget on the suitability of Rel inhibitors for other B cell malignancies.
Dr. Furman has published over 40 papers in medical and clinical journals.
Johannes Zakrzewski, MD, is an Associate Scientist at the Center for Discovery and Innovation, Hackensack University Medical Center. Prior to joining the current post in 2018, Dr. Zakrzewski was an Assistant Attending Pediatrician at Memorial Sloan Kettering Cancer Center and Assistant Clinical Professor in Pediatrics at Weill Cornell Medical Center.
The Zakrzewski laboratory focuses on the development of innovative therapies for the treatment of myeloma, lymphoma, and other cancers, as well as T-cell deficiency. His laboratory provides a platform for interdisciplinary collaboration, integrating oncology, immunology, stem cell biology, bioengineering, and drug development.
Specifically, the Zakrzewski laboratory is investigating novel strategies for cancer immunotherapy and immunosurveillance by exploiting the endogenous capacity of the thymus to generate genetically modified T cells and harnessing advances in gene therapy and chimeric antigen receptor technology.
In collaboration with ImmuneTarget Inc., Dr. Zakrzewski’s team is pursuing a drug development program aimed at improving the understanding of NF-κB and oxidative stress as therapeutic targets in multiple myeloma and other cancers.